Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT06083883
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 39
- Registration Number
- NCT06079164
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 404
- Registration Number
- NCT06072612
- Locations
- 🇺🇸
Sheboygan Cancer & Blood Specialists, Sheboygan, Wisconsin, United States
🇺🇸Hoag Hospital Center, Irvine, California, United States
🇺🇸Hoag Hospital Irvine, Irvine, California, United States
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
- Conditions
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT06066424
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT06066359
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06056752
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 20
- Registration Number
- NCT06056102
- Locations
- 🇺🇸
NYU Langone Health (Site #: 71177), New York, New York, United States
🇺🇸Massachusetts General Hospital: Transplantation (Site #: 71107), Boston, Massachusetts, United States
🇺🇸University of Pennsylvania Medical Center (Site #: 71111), Philadelphia, Pennsylvania, United States
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3680
- Registration Number
- NCT06058377
- Locations
- 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
- Conditions
- Interventions
- Drug: BendamustineProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyBiological: T-cell Receptor-engineered T-cells
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06043713
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1130
- Registration Number
- NCT06047080
- Locations
- 🇩🇪
Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany
🇺🇸Kaiser Permanente Medical Ctr, Vallejo, California, United States
🇺🇸St. Luke's Hospital, Chesterfield, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.